Skip to main content
Innovations Inspired by
life
Search
Menu
Search
Hamburger
Our Company
Who we are
History
Culture
Board of Directors
Leadership Team
OUR RESEARCH
Therapeutic focus
Delivery Technologies
Research Programs
R&D Pipeline
Our Medicines
Xelpros®
Elepsia® XR
Business Development
Strategy
Partner with us
Investors
Who we are
Financials
Annual reports
Presentations
Chairman's Speech
Committees of BOD's
Shareholding pattern
Announcements & Disclosures
Policies & Codes
Listing Information
Board of Directors
FAQ’s
Investors Contact
Go green
IEPF
Media
Press Releases
Presentations
Careers
Overview
Apply Now
Contact Us
Media
»
Press Releases
Media
Press Releases
Presentations
Press Releases
01-Jul-2019
SPARC Announces U.S. FDA Acceptance of NDA for TaclantisTM (Paclitaxel Injection Concentrate for Suspension) for Filing and Regulatory Review
13-Mar-2019
HitGen and SPARC Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration
03-Dec-2018
Schrödinger and SPARC Announce Collaboration to Accelerate Neurodegeneration Drug Development Program
26-Nov-2018
SPARC Announces Top-line Results of Pivotal Bioequivalence Study for Paclitaxel Injection Concentrate for Suspension
14-Sep-2018
Sun Pharma and SPARC Announce US FDA Approval of XELPROS™ to Treat Open-angle Glaucoma or Ocular Hypertension
10-Sep-2018
Audio playback of Investors Presentation
04-Jul-2018
Update on R&D Pipeline
06-Oct-2017
SPARC Provides Update on Pivotal Phase III Studies of Baclofen GRS for Treatment of Spasticity in Patients with Multiple Sclerosis
14-Jun-2017
SPARC Announces Top-line Results of Pivotal Peak Inspiratory Flow (PIF) study and Low Dose Pharmacokinetic (PK) Study for Salmeterol – Fluticasone Dry Powder Inhaler (SPARC DPI)
26-Aug-2016
Announcement - Receipt of reclassification approval from BSE
Pagination
First page
« First
Previous page
‹‹
Page
1
Current page
2
Page
3
Next page
››
Last page
Last »